BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22105899)

  • 1. Nodal status--its impact on prognosis in advanced ovarian cancer.
    Bachmann C; Bachmann S; Fehm T; Staebler A; Becker S; Rothmund R; Gardanis C; Grischke EM; Wallwiener D; Solomayer EF
    J Cancer Res Clin Oncol; 2012 Feb; 138(2):261-7. PubMed ID: 22105899
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: A population-based study.
    Zhou J; Zhang WW; Zhang QH; He ZY; Sun JY; Chen QH; Wu SG
    Int J Surg; 2018 Apr; 52():11-15. PubMed ID: 29432972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does systematic lymphadenectomy have a benefit on survival of suboptimally debulked patients with stage III ovarian carcinoma? A DEGOG* Study.
    Saygili U; Guclu S; Uslu T; Erten O; Ture S; Demir N
    J Surg Oncol; 2002 Nov; 81(3):132-7. PubMed ID: 12407725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of lymphadenectomy in the management of grossly apparent advanced stage epithelial ovarian cancer.
    Aletti GD; Dowdy S; Podratz KC; Cliby WA
    Am J Obstet Gynecol; 2006 Dec; 195(6):1862-8. PubMed ID: 17132488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relationship between retroperitoneal lymphadenectomy and survival in advanced ovarian cancer patients.
    Fang C; Zhang Y; Zhao L; Chen X; Xia L; Zhang P
    BMC Cancer; 2020 Jul; 20(1):654. PubMed ID: 32660444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic relevance of node metastases in optimally cytoreduced advanced ovarian cancer.
    Bachmann C; Brucker SY; Kraemer B; Rothmund R; Staebler A; Fend F; Wallwiener D; Grischke EM
    J Cancer Res Clin Oncol; 2015 Aug; 141(8):1475-80. PubMed ID: 25739827
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.
    Mahdi H; Moslemi-Kebria M; Levinson KL; Gojayev A; Lockhart D; Ali-Fehmi R; Munkarah AR
    Int J Gynecol Cancer; 2013 Sep; 23(7):1226-30. PubMed ID: 23736258
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relevance of pelvic and para-aortic node metastases in early-stage ovarian cancer.
    Bachmann C; Krämer B; Brucker SY; Stäbler A; Fend F; Wallwiener D; Grischke EM; Rothmund R
    Anticancer Res; 2014 Nov; 34(11):6735-8. PubMed ID: 25368283
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The investigation of the factors affecting retroperitoneal lymph node metastasis in stage IIIC and IV epithelial ovarian cancer.
    Yavuzcan A; Baloglu A; Cetinkaya B
    Arch Gynecol Obstet; 2009 Dec; 280(6):939-44. PubMed ID: 19306011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases.
    di Re F; Baiocchi G; Fontanelli R; Grosso G; Cobellis L; Raspagliesi F; di Re E
    Gynecol Oncol; 1996 Sep; 62(3):360-5. PubMed ID: 8812533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
    Quan C; Chen X; Wen H; Wu X; Li J
    BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph Node Involvement Pattern and Survival Differences of FIGO IIIC and FIGO IIIA1 Ovarian Cancer Patients After Primary Complete Tumor Debulking Surgery: A 10-Year Retrospective Analysis of the Tumor Bank Ovarian Cancer Network.
    Gasimli K; Braicu EI; Nassir M; Richter R; Babayeva A; Chekerov R; Darb-Esfahani S; Sehouli J; Muallem MZ
    Ann Surg Oncol; 2016 Apr; 23(4):1279-86. PubMed ID: 26832880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of celiac lymph node involvement in patients after frontline treatment for advanced ovarian cancer.
    Angeles MA; Ferron G; Cabarrou B; Balague G; Martínez-Gómez C; Gladieff L; Pomel C; Martinez A
    Eur J Surg Oncol; 2019 Aug; 45(8):1410-1416. PubMed ID: 30857876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is there any therapeutic role of pelvic and para-aortic lymphadenectomy in apparent early stage epithelial ovarian cancer?
    Bizzarri N; du Bois A; Fruscio R; De Felice F; De Iaco P; Casarin J; Vizza E; Chiantera V; Corrado G; Cianci S; Magni S; Ferrari D; Giuliani D; Harter P; Ataseven B; Bommert M; Perrone AM; Scambia G; Fagotti A
    Gynecol Oncol; 2021 Jan; 160(1):56-63. PubMed ID: 33168305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial.
    Panici PB; Maggioni A; Hacker N; Landoni F; Ackermann S; Campagnutta E; Tamussino K; Winter R; Pellegrino A; Greggi S; Angioli R; Manci N; Scambia G; Dell'Anna T; Fossati R; Floriani I; Rossi RS; Grassi R; Favalli G; Raspagliesi F; Giannarelli D; Martella L; Mangioni C
    J Natl Cancer Inst; 2005 Apr; 97(8):560-6. PubMed ID: 15840878
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic value of selective lymphadenectomy in interval debulking surgery for stage IIIc and IV epithelial ovarian cancer.
    Song N; Gao Y
    Int J Gynecol Cancer; 2019 May; 29(4):761-767. PubMed ID: 30850437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage lymphadenectomy in recurrent ovarian cancer patients: Analysis of clinical outcome and BRCA1/2 gene mutational status.
    Gallotta V; Bruno M; Conte C; Giudice MT; Davià F; Moro F; Zannoni GF; Fagotti A; De Bonis M; Capoluongo E; Scambia G; Ferrandina G
    Eur J Surg Oncol; 2020 Jul; 46(7):1327-1333. PubMed ID: 32085925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic factors analysis in patients with ovarian malignant germ cell tumor treated with fertility-preserving surgery].
    Yang ZJ; Wei RJ; Li L
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):898-904. PubMed ID: 23324188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment and prognostic analysis of ovarian cancer patients with isolated region of lymph node recurrence].
    Tu H; Huang H; Huang QD; Li Z; Feng YL; Liu JH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Dec; 47(12):928-33. PubMed ID: 23324194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Number of Removed Pelvic Lymph Nodes as a Prognostic Marker in FIGO Stage IB1 Cervical Cancer with Negative Lymph Nodes.
    Wang R; Tao X; Wu X; Jiang H; Xia H
    J Minim Invasive Gynecol; 2020; 27(4):946-952. PubMed ID: 31394263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.